乾癬（Psoriasis）治療のグローバル市場：画期的医薬品開発...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 6
2 The Case for Innovation 7
2.1 Growing Opportunities for Biologic Products 7
2.2 Diversification of Molecular Targets 7
2.3 Innovative First-in-Class Product Developments Remain Attractive 7
2.4 Changes in the Clinical and Commercial Environment Will be More Favorable to Products That Target Niche Indications and Patient Populations 8
2.5 Innovation in Psoriasis 8
3 Clinical and Commercial Landscape 9
3.1 Disease Introduction 9
3.2 Epidemiology 9
3.3 Etiology 10
3.3.1 Genetic Predisposition 10
3.3.2 Environmental Factors 10
3.4 Pathophysiology 10
3.4.1 Keratinocytes 10
3.4.2 Dendritic Cells 11
3.4.3 T-Cells 11
3.4.4 Angiogenesis 11
3.4.5 Growth Factors 11
3.5 Symptoms and Co-morbidities 12
3.5.1 Skin Manifestations 12
3.5.2 Psoriatic Arthritis 12
3.5.3 Uveitis 12
3.5.4 Cardiovascular Disease 12
3.5.5 Psychological Impact 12
3.6 Diagnosis of Psoriasis 13
3.6.1 Diagnosis of Psoriatic Arthritis 13
3.7 Treatment 13
3.7.1 Pharmacological Therapies 13
3.7.2 Topical Medications 13
3.7.3 Systemic Medications 14
3.7.4 Non-Pharmacological Therapies 14
3.7.5 Combination and Rotational Therapies 15
3.8 Overview of Marketed Products for Psoriasis 16
3.8.1 Oral Non-Biologic DMARDs 16
3.8.2 Off-Label Non-Biologic DMARDs 19
3.8.3 Biologics 19
3.8.4 Comparative Efficacy and Safety of Marketed Products 23
3.8.5 Unmet Need 26
4 Assessment of Psoriasis Pipeline and Innovation 27
4.1 Overview 27
4.2 Comparative Efficacy and Safety of Pipeline Programs 29
4.3 Comparative Distribution of Programs in the Psoriasis Market and Pipeline by Therapeutic Target Family 31
4.4 Comparative Distribution of Programs with First-in-Class and Established Molecular Targets 33
4.5 Pipeline Programs Targeting Established Molecular Targets 36
4.6 First-in-Class Pipeline Programs with Novel Molecular Targets 38
5 First-in-Class Target and Pipeline Program Evaluation 40
5.1 Cytokines and Receptors 40
5.1.1 Pipeline Programs Targeting Tumor Necrosis Factor Receptors 40
5.1.2 Pipeline Programs Targeting Interleukin-6 42
5.1.3 Pipeline Programs Targeting Interleukin-8 43
5.1.4 Pipeline Programs Targeting Interleukin-17 44
5.1.5 Pipeline Programs Targeting Interferon-γ 45
5.2 B and T Cell Antigens 46
5.2.1 Pipeline Programs Targeting Cluster of Differentiation 4 46
5.2.2 Pipeline Programs Targeting Cluster of Differentiation 28 47
5.3 Intracellular Kinases 48
5.3.1 Pipeline Programs Targeting Interleukin-1 Receptor-Associated Kinase-4 48
5.4 Nuclear Receptors 49
5.4.1 Pipeline Programs Targeting Retinoic Acid Receptor-Related Orphan Receptor 49
5.5 Growth Factors 51
5.5.1 Pipeline Programs Targeting Transforming Growth Factor-β Receptor 51
5.5.2 Pipeline Programs Targeting Insulin Receptor Substrate 52
5.6 Ion Channels 53
5.6.1 Pipeline Programs Targeting Calcium Release-Activated Calcium Channel 53
5.7 Integrins 54
5.7.1 Pipeline Programs Targeting Vascular Adhesion Protein-1 54
5.8 Other 55
5.8.1 Pipeline Programs Targeting F1F0-Adenosine Triphosphate Synthase 55
5.8.2 Pipeline Programs Targeting Cathepsin S 56
5.9 Conclusion 57
6 Deals and Strategic Consolidations 59
6.1 Licensing Agreements 59
6.2 Major Co-development Deals 62
6.3 First-in-Class Developmental Programs Not Involved in Co-Development or Licensing Deals 65
7 Appendix 66
7.1 Abbreviations 66
7.2 References 68
7.3 Methodology 76
7.4 Contact Us 76
7.5 Disclaimer 77